Myasthenia Gravis Diagnosis and Treatment Market
Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, Share & Trends Analysis by Treatment (Medication, Surgery, and Others), by Diagnosis (Edrophonium Tests, Blood Tests, Pulmonary Function Tests, Electrodiagnostic, Imaging, and Others), and by End-Users (Hospitals, Clinics, and Others), Forecast Period (2026-2035)
Industry Overview
Myasthenia gravis (MG) diagnosis and treatment market was valued at $ 12,000.0 million in 2025 and is projected to reach $17,186.2 million by 2035, growing at a CAGR of 3.8% during the forecast Period (2026-2035). The market is experiencing steady growth due to increasing awareness, rising prevalence of autoimmune disorders, and advancements in diagnostic and therapeutic technologies. Key diagnostic methods include blood tests, electrodiagnostic procedures, pulmonary function tests, and imaging, enabling early and accurate detection. Treatment options range from corticosteroids and immunosuppressants to targeted therapies such as monoclonal antibodies. The market is driven by improved healthcare infrastructure, growing adoption of novel therapies, and supportive regulatory frameworks, particularly in developed regions. Expansion in emerging economies and ongoing research further contribute to the overall market development.
Market Dynamics
Increasing Prevalence and Early Diagnosis of Myasthenia Gravis
The global MG diagnosis and treatment market is being strongly driven by the rising prevalence of myasthenia gravis and related autoimmune disorders worldwide. Improved epidemiological understanding, better disease surveillance, and enhanced diagnostics have resulted in more cases being detected earlier than before, increasing the overall diagnosed patient pool seeking treatment. As accurate diagnostic tools like antibody blood tests, single-fiber electromyography (SFEMG), and advanced neurophysiological tests become more widely used, early detection improves clinical outcomes and raises demand for appropriate treatment regimens. This trend of growing incidence combined with earlier and more accurate detection continues to expand the market’s scope for both diagnostics and therapeutics.
Advancements in Diagnostic Technologies and Targeted Therapeutics
Technological progress in both diagnostic capabilities and treatment modalities is another fundamental driver of the MG market. On the diagnostic side, tools such as next?generation antibody assays and refined electromyography techniques have significantly increased sensitivity and specificity, enabling clinicians to diagnose MG earlier and with greater confidence. Likewise, the development and regulatory approvals of novel targeted therapies, particularly biologics such as monoclonal antibodies (e.g., complement inhibitors, FcRn blockers), have reshaped the treatment landscape by offering more effective and often safer options compared with traditional corticosteroids and immunosuppressants. These advancements not only improve patient outcomes but also stimulate investment from pharmaceutical companies into R&D, supporting continuous market growth.
Growing Awareness, Regulatory Support, and Healthcare Infrastructure Expansion
Greater patient and clinician awareness, combined with favorable regulatory support and expanding healthcare infrastructure, is driving increased adoption of both MG diagnostics and treatments. Awareness initiatives by patient advocacy groups and healthcare bodies help reduce diagnostic delays and increase demand for comprehensive care solutions. At the same time, regulatory incentives — including faster approvals for orphan and rare?disease therapies — encourage pharmaceutical innovation and broaden market offerings. Improvements in healthcare infrastructure, especially in emerging economies, further facilitate access to advanced diagnostic tests and novel therapies, expanding market penetration geographically.
Market Segmentation
- Based on the treatment, the market is segmented into medication, surgery, and others.
- Based on the diagnosis, the market is segmented into edrophonium tests, blood tests, pulmonary function tests, electrodiagnostic, imaging, and others.
- Based on the end-user, the market is segmented into hospitals, clinics, and others.
Medication Segment to Grow at a Considerable Market Share
Medication segment under Treatment emerges as the largest single segment driving the market. This dominance is primarily owing medications including traditional agents like cholinesterase inhibitors and corticosteroids as well as a broad range of immunosuppressants and novel targeted therapiesconstitute the core of MG management globally. Most patients with MG rely on pharmacotherapy as the first?line and long?term strategy to manage neuromuscular weakness, suppress abnormal immune activity, and improve quality of life. Medications are widely prescribed across healthcare settings due to their relative accessibility, established clinical efficacy, and integration into standard care protocols, contributing a significantly larger share of overall market revenue compared with individual diagnostic modalities or specific end?user categories. The high utilization of drug therapies in both generalized and ocular MG cases, along with ongoing launches of biologics and immunomodulators, further reinforces the dominant position of the medication segment in the global MG market landscape.
Blood Tests: A Key Segment in Market Growth
The blood tests segment under the diagnosis category is witnessing the most significant growth in the global MG diagnosis and treatment market. Blood tests, particularly antibody testing for acetylcholine receptor (AChR) and muscle-specific kinase (MuSK) antibodies, are widely recognized for their high sensitivity and specificity in confirming MG. These tests are minimally invasive, relatively quick, and can be conducted in routine clinical settings, making them highly preferred by healthcare providers and patients alike. Increasing awareness among clinicians about the importance of early and accurate diagnosis, coupled with advancements in laboratory technologies and automated testing platforms, has further boosted the adoption of blood tests. The rising prevalence of MG, especially in aging populations and among individuals with autoimmune predispositions, has also contributed to the growing demand for reliable serological diagnostics. Additionally, blood tests are often used to monitor disease progression and response to therapy, which strengthens their utility throughout the patient care continuum. As a result, the blood tests segment not only leads diagnostic adoption but also acts as a gateway for timely treatment interventions, driving overall market growth and establishing itself as a cornerstone of the MG diagnostic and therapeutic landscape.
Regional Outlook
The global myasthenia gravis (MG) diagnosis and treatment market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region to Hold a Substantial Growth Rate
In North America, the US dominant country in the global myasthenia gravis (MG) diagnosis and treatment market, owing to its well-established healthcare infrastructure, high healthcare expenditure, and strong presence of key pharmaceutical and diagnostic companies. The country has a robust network of specialized hospitals, clinics, and research centers that focus on rare autoimmune disorders, enabling early diagnosis and advanced treatment of MG. Widespread awareness among healthcare professionals and patients, combined with efficient reimbursement policies and insurance coverage, facilitates greater access to both conventional therapies like corticosteroids and immunosuppressants and newer targeted treatments, including monoclonal antibodies and complement inhibitors.
Additionally, the US is at the forefront of research and development, with continuous clinical trials aimed at developing novel therapies and improving diagnostic accuracy, particularly through antibody testing and advanced electrodiagnostic techniques. The regulatory framework in the US, including fast-track approvals for orphan drugs, further supports innovation and market growth. Rising incidence of autoimmune disorders, coupled with technological advancements in diagnostics and therapeutics, reinforces the US market’s leadership. Collectively, these factors position the US as the largest and most influential contributor to the global MG diagnosis and treatment market, setting trends that often influence adoption and growth patterns in other regions.
Market Players Outlook
The major companies operating in the global myasthenia gravis (MG) diagnosis and treatment market include AstraZeneca PLC, argenx SE, Johnson & Johnson (Janssen), Novartis AG, UCB Pharma, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.
Recent Development
- In December 2025, FDA has approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis (gMG) who test positive for anti-AChR and anti-MuSK antibodies. This marks the first CD19-targeted B cell therapy for gMG, requiring only two annual doses after initial loading doses. gMG is an autoimmune disorder affecting approximately 80,000 to 100,000 individuals in the US, leading to fluctuating muscle weakness due to autoantibodies from CD19+ B cells. The approval is based on the Myasthenia Gravis Inebilizumab Trial (MINT), which demonstrated significant improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores, including a 1.9-point improvement at Week 26 compared to placebo, with sustained benefits for AChR+ patients through Week 52.
- In May 2025, Nipocalimab, marketed as Imaavy, received FDA approval for treating generalized myasthenia gravis (MG) in patients aged 12 and older with specific positive antibodies. MG is a chronic autoimmune disease that leads to muscle weakness, exacerbated by activity. The approval is based on positive results from the phase 3 Vivacity-MG3 clinical trial, which found that nipocalimab combined with standard care significantly improved disease control and maintained benefits over 20 months. The drug is an FcRn-blocking monoclonal antibody that lowers immunoglobulin G levels, achieving up to 75% reduction in autoantibody levels within 24 weeks while showing favorable safety profiles.
The Report Covers
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global myasthenia gravis (MG) diagnosis and treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Sales Analysis – Treatment | Diagnosis | End-Users ($ Million)
- Myasthenia Gravis (MG) Diagnosis and Treatment Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Myasthenia Gravis (MG) Diagnosis and Treatment Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Myasthenia Gravis (MG) Diagnosis and Treatment Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Myasthenia Gravis (MG) Diagnosis and Treatment Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Myasthenia Gravis (MG) Diagnosis and Treatment Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Myasthenia Gravis (MG) Diagnosis and Treatment Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Myasthenia Gravis (MG) Diagnosis and Treatment Market Revenue and Share by Manufacturers
- Myasthenia Gravis (MG) Diagnosis and Treatment Diagnosis Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- AstraZeneca PLC
- Overview
- Diagnosis Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- argenx SE
- Overview
- Diagnosis Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Johnson & Johnson (Janssen)
- Overview
- Diagnosis Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis AG
- Overview
- Diagnosis Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- UCB Pharma
- Overview
- Diagnosis Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Diagnosis Launch
- Partnership And Collaboration
- AstraZeneca PLC
- Key Company Analysis
- Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Sales Analysis by Treatment ($ Million)
- Medication
- Cholinesterase Inhibitors
- Corticosteroids
- Immunosuppressants
- Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Sales Analysis by Diagnosis ($ Million)
- Edrophonium Tests
- Blood Tests
- Pulmonary Function Tests
- Electrodiagnostic
- Imaging
- Others
- Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Sales Analysis by End-User ($ Million)
- Hospitals
- Clinics
- Others
- Regional Analysis
- North American Myasthenia Gravis (MG) Diagnosis and Treatment Market Sales Analysis – Treatment | Diagnosis | End-Users | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Myasthenia Gravis (MG) Diagnosis and Treatment Market Sales Analysis – Treatment | Diagnosis | End-Users | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Myasthenia Gravis (MG) Diagnosis and Treatment Market Sales Analysis – Treatment | Diagnosis | End-Users | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Myasthenia Gravis (MG) Diagnosis and Treatment Market Sales Analysis – Treatment | Diagnosis | End-Users | Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Alexion Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- argenx SE
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bausch Health Companies Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cartesian Therapeutics
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Chugai Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hoffmann-La Roche Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Grifols S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Immunovant Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck KGaA
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Mitsubishi Tanabe Pharma
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Regeneron Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- RemeGen
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- UCB Pharma
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
1. Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by Treatment, 2025–2035 ($ Million)
2. Global Medication For Myasthenia Gravis (MG) Diagnosis and Treatment Market Research And Analysis By Region, 2025–2035 ($ Million)
3. Global Cholinesterase Inhibitors For Myasthenia Gravis (MG) Diagnosis and Treatment Market Research And Analysis By Region, 2025–2035 ($ Million)
4. Global Corticosteroids For Myasthenia Gravis (MG) Diagnosis and Treatment Market Research And Analysis By Region, 2025–2035 ($ Million)
5. Global Immunosuppressants For Myasthenia Gravis (MG) Diagnosis and Treatment Market Research And Analysis By Region, 2025–2035 ($ Million)
6. Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by Diagnosis, 2025–2035 ($ Million)
7. Global Edrophonium Tests In Myasthenia Gravis (MG) Diagnosis and Treatment Market Research And Analysis By Region, 2025–2035 ($ Million)
8. Global Blood Tests In Myasthenia Gravis (MG) Diagnosis and Treatment Market Research And Analysis By Region, 2025–2035 ($ Million)
9. Global Pulmonary Function Tests In Myasthenia Gravis (MG) Diagnosis and Treatment Market Research And Analysis By Region, 2025–2035 ($ Million)
10. Global Electrodiagnostic In Myasthenia Gravis (MG) Diagnosis and Treatment Market Research And Analysis By Region, 2025–2035 ($ Million)
11. Global Imaging In Myasthenia Gravis (MG) Diagnosis and Treatment Market Research And Analysis By Region, 2025–2035 ($ Million)
12. Global Other Diagnosis Myasthenia Gravis (MG) Diagnosis and Treatment Market Research And Analysis By Region, 2025–2035 ($ Million)
13. Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by End-User, 2025–2035 ($ Million)
14. Global Myasthenia Gravis (MG) Diagnosis and Treatment For Hospitals Market Research And Analysis By Region, 2025–2035 ($ Million)
15. Global Myasthenia Gravis (MG) Diagnosis and Treatment For Clinics Market Research And Analysis By Region, 2025–2035 ($ Million)
16. Global Myasthenia Gravis (MG) Diagnosis and Treatment For Other End User Market Research And Analysis By Region, 2025–2035 ($ Million)
17. Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
18. North American Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by Treatment, 2025–2035 ($ Million)
19. North American Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by Diagnosis, 2025–2035 ($ Million)
20. North American Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by End-User, 2025–2035 ($ Million)
21. European Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by Treatment, 2025–2035 ($ Million)
22. European Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by Diagnosis, 2025–2035 ($ Million)
23. European Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by End-User, 2025–2035 ($ Million)
24. Asia-Pacific Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by Treatment, 2025–2035 ($ Million)
25. Asia-Pacific Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by Diagnosis, 2025–2035 ($ Million)
26. Asia-Pacific Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by End-User, 2025–2035 ($ Million)
27. Rest of the World Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
28. Rest of the World Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by Treatment, 2025–2035 ($ Million)
29. Rest of the World Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by Diagnosis, 2025–2035 ($ Million)
30. Rest of the World Myasthenia Gravis (MG) Diagnosis and Treatment Market Research and Analysis by End-User, 2025–2035 ($ Million)
1. Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Share By Treatment, 2025 Vs 2035 (%)
2. Global Medication For Myasthenia Gravis (MG) Diagnosis and Treatment Market Share By Region, 2025 Vs 2035 (%)
3. Global Cholinesterase Inhibitors For Myasthenia Gravis (MG) Diagnosis and Treatment Market Share By Region, 2025 Vs 2035 (%)
4. Global Corticosteroids For Myasthenia Gravis (MG) Diagnosis and Treatment Market Share By Region, 2025 Vs 2035 (%)
5. Global Immunosuppressants For Myasthenia Gravis (MG) Diagnosis and Treatment Market Share By Region, 2025 Vs 2035 (%)
6. Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Share By Diagnosis, 2025 Vs 2035 (%)
7. Global Edrophonium Tests In Myasthenia Gravis (MG) Diagnosis and Treatment Market Share By Region, 2025 Vs 2035 (%)
8. Global Blood Tests In Myasthenia Gravis (MG) Diagnosis and Treatment Market Share By Region, 2025 Vs 2035 (%)
9. Global Pulmonary Function Tests In Myasthenia Gravis (MG) Diagnosis and Treatment Market Share By Region, 2025 Vs 2035 (%)
10. Global Electrodiagnostic In Myasthenia Gravis (MG) Diagnosis and Treatment Market Share By Region, 2025 Vs 2035 (%)
11. Global Imaging In Myasthenia Gravis (MG) Diagnosis and Treatment Market Share By Region, 2025 Vs 2035 (%)
12. Global Other Diagnosis Myasthenia Gravis (MG) Diagnosis and Treatment Market Share By Region, 2025 Vs 2035 (%)
13. Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Share By End-User, 2025 Vs 2035 (%)
14. Global Myasthenia Gravis (MG) Diagnosis and Treatment For Hospitals Market Share By Region, 2025 Vs 2035 (%)
15. Global Myasthenia Gravis (MG) Diagnosis and Treatment For Clinics Market Share By Region, 2025 Vs 2035 (%)
16. Global Myasthenia Gravis (MG) Diagnosis and Treatment For Other End User Market Share By Region, 2025 Vs 2035 (%)
17. Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Share By Region, 2025 Vs 2035 (%)
18. US Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
19. Canada Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
20. UK Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
21. France Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
22. Germany Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
23. Italy Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
24. Spain Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
25. Russia Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
26. Rest of Europe Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
27. India Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
28. China Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
29. Japan Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
30. South Korea Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
31. Australia and New Zealand Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
32. ASEAN Economies Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
33. Rest of Asia-Pacific Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
34. Latin America Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
35. Middle East and Africa Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
